Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
NCT02901899Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Nov 2016
- Primary completion
- Apr 2020
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of guadecitabine in ovarian cancer, sponsored by Northwestern University. Started Nov 2016; status: completed.
02
Drugs
guadecitabine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02901899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901899.